Abivax announced highly positive Phase 3 results for its orally available miRNA therapy obefazimod targeting moderately to severely active ulcerative colitis (UC). The pooled remission rate reached 16.4% over placebo at eight weeks, with a safety profile consistent with earlier findings. The data elevates obefazimod as a leading oral therapeutic candidate in the inflammatory bowel disease field, which is forecasted to reach $30 billion by 2030. A long-term maintenance trial is underway, with regulatory submissions anticipated in late 2026. Following these announcements, Abivax’s shares surged dramatically by over 500%, reflecting investor confidence in the potential market impact of this novel therapeutic mechanism.